Allogene and MD Anderson Announce a 5-Year Collaboration to Develop Allogeneic CAR-Ts
Here is a brief preview of this blast: On Thursday, October 15, Allogene announced (press release) a five-year collaboration with the MD Anderson Cancer Center for the preclinical and clinical development of Allogene’s AlloCAR-T candidates. Below, Celltelligence provides insights on the significance of this collaboration for Allogene’s clinical pipeline.